FDA Approves Jazz's Ziihera in First-Line HER2+ GEA, Setting a New Standard of Care

The FDA on Tuesday approved Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii) for first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA), clearing two regimens that together establish a new front-line standard of care in a cancer diagnosed in roughly 31,000 U.S. patients each year.

The approval covers Ziihera plus BeOne Medicines’ Tevimbra (tislelizumab) and fluoropyrimidine- and platinum-containing chemotherapy for tumors that are HER2+ IHC 3+ or IHC 2+/ISH+, and Ziihera plus chemotherapy for HER2+ IHC 3+ disease. Both are approved regardless of PD-L1 status, making Ziihera the first and only bispecific HER2-targeted antibody cleared in the front-line GEA setting.

The decision lands on the drug’s August 25 PDUFA date and follows the Phase 3 HERIZON-GEA-01 trial, published in the New England Journal of Medicine and first presented at ASCO GI 2026. The Ziihera combinations cut the risk of disease progression or death by 35%, extending median progression-free survival to 12.4 months versus 8.1 months for trastuzumab plus chemotherapy. The triplet arm showed a 28% reduction in the risk of death, with median overall survival of 26.4 months versus 19.2 months, a greater-than-seven-month gain and the longest median survival reported in a Phase 3 trial in HER2+ advanced GEA.

Trastuzumab plus chemotherapy has been the standard of care since 2010. Ziihera’s bispecific design binds two distinct HER2 epitopes, and the data translate into a 7.2-month overall survival improvement over the incumbent.

Jazz shares rose about 3.5% in Tuesday trading to roughly $263. The approval expands Ziihera’s footprint from its existing indication, previously treated HER2-positive biliary tract cancer, which generated $24.8 million in full-year 2025 sales. The new label reaches a much larger population, as roughly 20% of GEA patients have HER2-positive disease.

Safety mirrors prior zanidatamab studies. Diarrhea was the most common adverse reaction, managed with loperamide prophylaxis and dose modifications, with few Ziihera discontinuations. The label carries boxed warnings for diarrhea and embryo-fetal toxicity.

For context on the data and why the label matters to the broader Jazz story, see our pre-decision analysis of the Ziihera GEA PDUFA. Jazz will host an investor webcast Tuesday at 4:30 p.m. ET to discuss the approval and the zanidatamab development program.

What It Means for the Trade

The bull math on this label is straightforward and worth spelling out. Roughly 31,000 U.S. GEA diagnoses a year, ~20% HER2-positive — call it 6,000-plus U.S. front-line patients annually, before you count Europe and the other territories Jazz holds. Against a first-line standard (trastuzumab plus chemo) that’s been static since 2010, a 7.2-month median OS improvement is the kind of magnitude that converts prescribing habits quickly: oncologists in this indication have been waiting sixteen years for something better, and there’s no entrenched immunotherapy incumbency to displace in HER2+ IHC 3+ disease, where pembrolizumab-based benefit is weakest.

What the label means for Jazz financially: the biliary tract indication was a $24.8 million orphan beachhead. First-line GEA is the real launch. Analysts following the story will now build the drug toward several hundred million in peak sales if uptake resembles typical biomarker-driven oncology launches — with the triplet (Ziihera + Tevimbra + chemo) capturing the PD-L1-all-comer population and the doublet covering IHC 3+. The gating factors are speed of HER2 testing adoption in GEA (compliance with IHC/ISH screening is inconsistent in community settings) and payer coverage for a bispecific plus PD-1 plus chemo stack.

Two structural points matter more than the headline numbers. First, both regimens approved regardless of PD-L1 status removes the biggest commercial friction point — no companion diagnostic knot for the triplet. Second, HERIZON-GEA-01’s OS co-primary was met at second interim (announced August 31), so the label rests on a fully completed Phase 3, not accelerated-approval IOUs. That durability matters for pricing negotiations and for EU/Asia expansion.

Company and Franchise Context

Jazz has been running a deliberate pivot: away from narcolepsy-dependence (Xywav/Xyrem patent-cliff overhang, plus the ongoing high-sodium oxybate franchise defense) and toward oncology and neuroscience breadth. The oncology pillar currently leans on Zepzelca in SCLC (where the first-line IMforte win was offset by the second-line LAGOON failure and U.S. withdrawal), Rylaze in ALL, and now Ziihera as the growth engine. A clean, fully-powered first-line GEA standard-of-care label is the strongest commercial asset Jazz has added since acquiring the GW cannabidiol platform that became Epidiolex.

Note the competitive vacuum this lands in. The only other front-line HER2-directed option in GEA was trastuzumab itself; Enhertu’s GEA data are in the second-line HER2+ setting, and follow-on bispecifics or ADCs in first-line HER2+ GEA are years behind. Zanidatamab’s biparatopic binding — two HER2 epitopes simultaneously — drives stronger receptor clustering and internalization than trastuzumab’s single-epitope binding, which is the mechanistic story behind the head-to-head win. That mechanism also underpins the biliary tract label and the earlier HER2-positive breast and gynecologic programs Jazz has explored.

Risks and What Could Go Wrong

Three things can blunt this. First, Enhertu. The DESTINY-Gastric program and any first-line GEA ambitions from Daiichi/AstraZeneca are the credible long-term threat; if an ADC demonstrates superiority in first-line HER2+ GEA, zanidatamab’s window as the unchallenged standard narrows to the time it takes to run that trial. Second, the boxed warnings — diarrhea management is a real-world compliance tax, and embryo-fetal toxicity requires pregnancy surveillance infrastructure that community practices handle inconsistently; watch discontinuation rates in the launch data. Third, execution and concentration: Jazz paid real money for zanidatamab (the Zymeworks license plus milestones), and the $820 million Actio Biosciences acquisition announced in August means Jazz is spending on pipeline while Xyrem franchise economics decay. If Ziihera’s launch curve disappoints, Jazz’s sum-of-the-parts gets stressed from both directions.

The launch metrics to track quarterly: number of HERIZON patients on therapy, HER2 testing rates in GEA, U.S. new-patient starts for both regimens, and any early EU filings. First-two-quarters prescription trajectory will tell you whether the 26.4-month OS number is doing the selling, or whether Jazz’s commercial engine needs to.